Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients
Authors:
Open Access
- 1 February 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (2) , 539-545
Abstract
Infection is the Achilles heel of peritoneal dialysis. Exit site mupirocin prevents Staphylococcus aureus peritoneal dialysis (PD) infections but does not reduce Pseudomonas aeruginosa or other Gram-negative infections, which are associated with considerable morbidity and sometimes death. Patients from three centers (53% incident to PD and 47% prevalent) were randomized in a double-blinded manner to daily mupirocin or gentamicin cream to the catheter exit site. Infections were tracked prospectively by organism and expressed as episodes per dialysis-year at risk. A total of 133 patients were randomized, 67 to gentamicin and 66 to mupirocin cream. Catheter infection rates were 0.23/yr with gentamicin cream versus 0.54/yr with mupirocin (P = 0.005). Time to first catheter infection was longer using gentamicin (P = 0.03). There were no P. aeruginosa catheter infections using gentamicin compared with 0.11/yr using mupirocin (P < 0.003). S. aureus exit site infections were infrequent in both groups (0.06 and 0.08/yr; P = 0.44). Peritonitis rates were 0.34/yr versus 0.52/yr (P = 0.03), with a striking decrease in Gram-negative peritonitis (0.02/yr versus 0.15/yr; P = 0.003) using gentamicin compared with mupirocin cream, respectively. Gentamicin use was a significant predictor of lower peritonitis rates (relative risk, 0.52; 95% confidence interval, 0.29 to 0.93; P < 0.03), controlling for center and incident versus prevalent patients. Gentamicin cream applied daily to the peritoneal catheter exit site reduced P. aeruginosa and other Gram-negative catheter infections and reduced peritonitis by 35%, particularly Gram-negative organisms. Gentamicin cream was as effective as mupirocin in preventing S. aureus infections. Daily gentamicin cream at the exit site should be the prophylaxis of choice for PD patients.Keywords
This publication has 12 references indexed in Scilit:
- Staphylococcus Aureus Prophylaxis and Trends in Gram-Negative Infections in Peritoneal Dialysis PatientsPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2003
- Emergence of Mupirocin-Resistant Staphylococcus Aureus in Chronic Peritoneal Dialysis Patients using Mupirocin Prophylaxis to Prevent Exit-Site InfectionPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2001
- Application of Mupirocin Cream at the Catheter Exit Site Reduces Exit-Site Infections and Peritonitis in Peritoneal Dialysis PatientsPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2000
- Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 UpdatePeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2000
- Rate of Decline of Residual Renal Function in Patients on Continuous Peritoneal Dialysis and Factors Affecting ItPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2000
- Outcome following Staphylococcal PeritonitisPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2000
- Recurrent Infection and Catheter Loss in Patients on Continuous Ambulatory Peritoneal DialysisPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1999
- Pseudomonas Exit-Site Infections in CAPD Patients: Evolution and Outcome of TreatmentPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1998
- Continuous Ambulatory Peritoneal Dialysis Catheter Infections: Diagnosis and ManagementPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1994
- Staphylococcus Aureus Nasal Carriage, Exit-Site Infection and Catheter Loss in Patients Treated with Continuous Ambulatory Peritoneal Dialysis (CAPD)Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1989